Crinetics Pharmaceuticals Inc
$ 40.25
-1.83%
20 Apr - close price
- Market Cap 4,292,919,000 USD
- Current Price $ 40.25
- High / Low $ 40.88 / 40.00
- Stock P/E N/A
- Book Value 10.38
- EPS -4.95
- Next Earning Report 2026-05-07
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.25 %
- ROE -0.40 %
- 52 Week High 57.99
- 52 Week Low 25.83
About
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapies for rare endocrine diseases and endocrine-related tumors. The company is headquartered in San Diego, California.
Analyst Target Price
$83.50
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-04 | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-02-26 | 2024-11-12 | 2024-08-08 | 2024-05-09 | 2024-02-28 | 2023-11-07 | 2023-08-08 | 2023-05-04 |
| Reported EPS | -1.29 | -1.38 | -1.23 | -1.04 | -0.88 | -0.96 | -0.94 | -0.93 | -0.9 | -1.01 | -0.94 | -0.85 |
| Estimated EPS | -1.28 | -1.25 | -1.1 | -0.9523 | -0.8919 | -0.91 | -0.86 | -0.81 | -0.86 | -0.86 | -0.86 | -0.81 |
| Surprise | -0.01 | -0.13 | -0.13 | -0.0877 | 0.0119 | -0.05 | -0.08 | -0.12 | -0.04 | -0.15 | -0.08 | -0.04 |
| Surprise Percentage | -0.7813% | -10.4% | -11.8182% | -9.2093% | 1.3342% | -5.4945% | -9.3023% | -14.8148% | -4.6512% | -17.4419% | -9.3023% | -4.9383% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-07 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -1.2 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CRNX
2026-04-14 20:39:55
Crinetics Pharmaceuticals, Inc. (CRNX) has filed a Rule 144 notice detailing a proposed sale of common stock. The filing indicates an exercise of stock options for 20,900 shares on April 14, 2026, and also discloses multiple prior 10b5-1 sales executed by Jeff Knight on March 16, April 8, and April 13, 2026, totaling over 99,000 shares. These transactions are considered routine procedural disclosures under Rule 144 and do not necessarily imply discretionary trading.
2026-04-14 04:09:44
Crinetics Pharmaceuticals, Inc. announced it will release its first quarter 2026 financial results on Thursday, May 7, 2026, after market close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss the financial results and provide a business update. Crinetics Pharmaceuticals is focused on developing therapies for endocrine diseases and endocrine-related tumors, with lead product PALSONIFY™ (paltusotine) approved for acromegaly.
2026-04-13 20:10:37
A Form 144 notice was filed for the sale of 4,434 shares of Crinetics Pharmaceuticals (CRNX) common stock by Morgan Stanley Smith Barney LLC, resulting from the exercise of stock options on April 13, 2026. The filing also disclosed prior 10b5-1 sales by Jeff Knight totaling 95,074 shares on April 8, 2026, and March 16, 2026, with detailed proceeds. These are routine administrative notifications for securities transactions by insiders.
2026-04-13 16:10:37
This article provides an in-depth analysis of Crinetics Pharmaceuticals Inc. (CRNX) using AI-generated signals and institutional trading strategies. It highlights a strong overweight bias across all horizons, identifies potential volatility zones, and offers specific entry/target/stop-loss parameters for position trading, momentum breakout, and risk hedging strategies. The analysis also includes multi-timeframe signal strengths with support and resistance levels.
2026-04-13 00:08:57
The article highlights top pharmaceutical companies identified by quantitative analysis, including Indivior, Liquidia, and Crinetics. It also notes Merck's acquisition of Terns for $6.7 billion, indicating significant activity in the pharmaceutical sector. This suggests a focus on both high-performing smaller companies and major consolidation efforts by industry giants.
2026-04-11 15:10:01
Crinetics Pharmaceuticals director Jeff Knight sold 85,163 shares of CRNX stock on April 8th for over $3.4 million, significantly reducing his stake in the company. This transaction was conducted under a Rule 10b5-1 trading plan. The company recently reported better-than-expected quarterly earnings but remains unprofitable, holding a "Moderate Buy" consensus rating from analysts with a target price of $76.63.
